Purchase Order 75N91018P00674

<p>The National Cancer Institute awarded a purchase order to Mayo Clinic on September 17, 2018, for $15,000 to obtain follow-up procedure and outcome information data from 1,000 women evaluated for abnormal uterine bleeding at Mayo Clinic. The order carries firm fixed-price pricing with no set-aside designation. Place of performance is Bethesda, Maryland. The ultimate completion date is September 16, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Mayo Clinic for $70,000 on September 22, 2017, for procurement of biosamples for analysis of suspected endometrial cancer and precursors. The order is firm fixed price with no set-aside designation. Performance occurs in Rochester, Minnesota, and the order completion date is September 21, 2018.</p>

<p>The National Cancer Institute awarded a purchase order to Mayo Clinic for $64,050.00 on August 22, 2016, for enrollment of women at increased risk of endometrial cancer, with an ultimate completion date of March 25, 2021. Work is performed at Mayo Clinic's facility in Bethesda, Maryland. The order is firm fixed price with no small business set-aside. The award involved de-obligation of funds from expiring FY2016 lines.</p>

This is a firm-fixed price purchase order contract awarded by the National Cancer Institute, a component of the National Institutes of Health, to the Mayo Clinic, a renowned non-profit academic medical center. The contract, valued at $2,995.37, is for abstracting follow-up procedures and outcome information for women with abnormal uterine bleeding from electronic medical records. The contract does not have a set-aside designation, reflecting Mayo Clinic's status as a large, established...

<p>The National Cancer Institute issued a purchase order to Mayo Clinic on March 1, 2018, for $6,400.00, with a firm fixed-price structure and an ultimate completion date of June 30, 2018. Place of performance is Montgomery Village, Maryland. The source does not specify the requirements or deliverables covered under this purchase order.</p>

<p>The National Cancer Institute awarded a purchase order to Mayo Clinic for $23,550.00 on September 1, 2017, for subtype classification and harmonization of lymphoid malignancies. Performance is located in Rochester, Minnesota, with an ultimate completion date of August 31, 2018. The order is firm fixed-price with no set-aside designation.</p>

The National Cancer Institute issued a $167,149.99 delivery order to Mayo Clinic on August 7, 2017, under the Pharmacokinetic and Pharmacology Evaluations for Cancer Patients parent IDIQ for pharmacokinetic and bioavailability studies of selected anticancer compounds in mice and pharmacological evaluations of agents in development for cancer patients. Place of performance is Rochester, Minnesota. The order's ultimate completion date is June 30, 2021. Pricing is cost with no fee. Performance...

This federal contract award, valued at $13,933.86, was issued by the National Cancer Institute (NCI) to the Mayo Clinic, a renowned non-profit academic medical center based in Rochester, Minnesota. The contract is for the whole-slide scanning of endometrial biopsy slides from women with endometrial cancer, hyperplasia, and benign changes. This contract is a firm-fixed-price purchase order and does not have a set-aside designation, reflecting Mayo Clinic's status as a large, established...

Mayo Clinic was awarded a cost-plus-fixed-fee delivery order against its indefinite delivery/indefinite quantity contract with the National Cancer Institute. The $1,996,069 order has a period of performance through July 2023 to support preclinical pharmacokinetic evaluations for the National Cancer Institute's Experimental Therapeutics program in Rochester, Minnesota. No set-aside designation was used for this order to further the agency's aim of aiding the development and approval of new cancer...

This is a firm-fixed price delivery order awarded by the National Cancer Institute (NCI) to Mayo Clinic, a renowned non-profit academic medical center. The contract, with a ceiling value of $76,500.00, supports the NCI's Cancer Genome Atlas (TCGA) program by providing tissue samples and data from various types of cancer. This order is part of a larger $9.9 million indefinite delivery/indefinite quantity (IDIQ) contract awarded to Mayo Clinic in 2021, which enables the NCI to procure research and...